fr   en

Tableaux synoptiques (en anglais)

Parcourir par date
Rechercher par mot clé
Date: 2010-02-17
Biotech partner: Roche Molecular Systems (Switzerland-USA)
Pharma Partner: Merck & Co (USA)
Type of agreement: * R&D
* licensing
* other
Compound: AmpliChip p53 Test
Disease area: cancers harboring a dysfunctional p53 gene
Nature of the agreement: Roche Molecular Systems and Merck & Co have announced a research collaboration providing Merck & Co access to Roche's developmental microarray-based AmpliChip p53 Test, which is designed to detect mutations in the tumor suppressor gene p53.
By identifying cancers that harbor a dysfunctional p53 gene, the companies aim to achieve better treatment outcomes in cancer patients by determining which patients are most likely to respond to certain investigational therapeutic candidates.

Go back to previous page